Studies on the antileishmanial properties of the antimicrobial peptides temporin A, B and 1Sa

Journal of Peptide Science

Volumn 17, Issue 11, 2011, Pages 751-755

  Chadbourne, Frances L ^a   Raleigh, Catriona ^a   Ali, Hayder Z ^a   Denny, Paul W ^a   Cobb, Steven L ^a  

^a DURHAM UNIVERSITY   (United Kingdom)

Author keywords

Antimicrobial peptides; Cutaneous leishmaniasis; Drug therapy; Leishmania mexicana; Temporins

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT; TEMPORIN 1SA; TEMPORIN A; TEMPORIN B; UNCLASSIFIED DRUG;

AMASTIGOTE; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; LEISHMANIA MEXICANA; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS;

ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIA; LEISHMANIASIS; PROTEINS;

HEXAPODA; LEISHMANIA MEXICANA; MAMMALIA; PROTOZOA;

EID: 80054988628     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1398     Document Type: Article

References (22)

1. WHO. WHO Neglected Tropical Diseases: [Accessed December 2010].
2. Stuart K, Brun R, Croft S, Fairlamb A, Gurtler RE, McKerrow J, Reed S, Tarleton R. Kinetoplastids: related protozoan pathogens, different diseases. J. Clin. Invest. 2008; 118: 1301-1310.
3. Kedzierski L, Sakthianandeswaren A, Cutris JM, Andrews PC, Junk PC, Kedzierski K. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr. Med. Chem. 2009; 16: 599-614.
4. Croft SL, Coombs GH. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trend. Parasitol. 2003; 19: 502-508.
5. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 2007; 5: 873-882.
6. Demicheli C, Ochoa R, da Silva JB, Falcao CA, Rossi-Bergmann B, de Melo AL, Sinisterra RD, Frezard F. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis. Antimicrob. Agents Chemother. 2004; 48: 100-103.
7. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 2006; 19: 111-126.
8. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health 2001; 6: 849-854.
9. Ephros M, Waldman E, Zilberstein D. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes. Antimicrob. Agents Chemother. 1997; 41: 1064-1068.
10. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans. R. Soc. Trop. Med. Hyg. 1999; 93: 319-323.
11. Bray PG, Barrett MP, Ward SA, de Koning HP. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trend. Parasitol. 2003; 19: 232-239.
12. Di Giorgio C, Faraut-Gambarelli F, Imbert A, Minodier P, Gasquet M, Dumon H. Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis. J Antimicrob. Chemother. 1999; 44: 71-76.
13. Cobb SL, Denny PW. Antimicrobial peptides for leishmaniasis. Curr. Opin. Invet. Drugs 2010; 11: 868-875.
14. McGwire BS, Kulkarni MM. Interactions of antimicrobial peptides with Leishmania and trypanosomes and their functional role in host parasitism. Exp. Parasitol. 2010; 126: 397-405.
15. Ulvatne H. Antimicrobial peptides-potential use in skin infections. Am. J. Clin. Dermatol. 2003; 4: 591-595.
16. Bates PA. Complete developmental cycle of Leishmania mexicana in axenic culture. Parasitology 1994; 108: 1-9.
17. Le Pape P, Pagniez F, Abdala-Valencia H. A new fluorometric method for anti-Leishmania drug screening on axenic amastigotes. Acta Parasitol. 2003; 48: 301-305.
18. Mangoni ML, Saugar JM, Dellisanti M, Barra D, Simmaco M, Rivas L. Temporins: small antimicrobial peptides with leishmanicidal activity. J. Biol. Chem. 2005; 280: 984-990.
19. Abbassi F, Oury B, Blasco T, Sereno D, Bolbach G, Nicolas P, Hani K, Amiche M, Ladram A. Isolation, characterization and molecular cloning of new temporins from the skin of the North African ranid Pelophylax saharica. Peptides 2009; 29: 1526-1533.
20. Mikus J, Steverding D. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol. Int. 2000; 48: 265-269.
21. Shimony O, Jaffe CL. Rapid fluorescent assay for screening drugs on Leishmania amastigotes. J. Microbiol. Methods. 2008; 75: 196-200.
22. de Oliveira-Silva F, de Morais-Teixeira E, Rabello A. Antileishmanial activity of azithromycin against Leishmania (Leishmania)amazonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi. Am. J. Trop. Med. Hyg. 2008; 78: 745-749.